Chinese Biotech Start-Up BioHeng Raises $15M Series A Round

Login to View

Nanjing-based biotechnology start-up BioHeng Biotech today announced that it has raised a RMB100 million (US$14.8 million) series A financing round from Decheng Capital, an early-stage life science-focused venture capital firm.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in